<?xml version='1.0' encoding='utf-8'?>
<document id="27518170"><sentence text="Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers."><entity charOffset="76-87" id="DDI-PubMed.27518170.s1.e0" text="Atomoxetine" /><entity charOffset="92-101" id="DDI-PubMed.27518170.s1.e1" text="Bupropion" /><pair ddi="false" e1="DDI-PubMed.27518170.s1.e0" e2="DDI-PubMed.27518170.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27518170.s1.e0" e2="DDI-PubMed.27518170.s1.e1" /></sentence><sentence text="To evaluate the impact of bupropion on the pharmacokinetic profile of atomoxetine and its main active metabolite (glucuronidated form), 4-hydroxyatomoxetine-O-glucuronide, in healthy volunteers"><entity charOffset="26-35" id="DDI-PubMed.27518170.s2.e0" text="bupropion" /><entity charOffset="70-81" id="DDI-PubMed.27518170.s2.e1" text="atomoxetine" /><pair ddi="false" e1="DDI-PubMed.27518170.s2.e0" e2="DDI-PubMed.27518170.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27518170.s2.e0" e2="DDI-PubMed.27518170.s2.e1" /></sentence><sentence text="" /><sentence text="An open-label, non-randomized, two-period, sequential clinical trial was conducted as follows: during Period I (Reference), each volunteer received a single oral dose of 25 mg atomoxetine, whilst during Period II (Test), a combination of 25 mg atomoxetine and 300 mg bupropion was administered to all volunteers, after a pretreatment regimen with bupropion for 7 days"><entity charOffset="176-187" id="DDI-PubMed.27518170.s4.e0" text="atomoxetine" /><entity charOffset="244-255" id="DDI-PubMed.27518170.s4.e1" text="atomoxetine" /><entity charOffset="267-276" id="DDI-PubMed.27518170.s4.e2" text="bupropion" /><entity charOffset="347-356" id="DDI-PubMed.27518170.s4.e3" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.27518170.s4.e0" e2="DDI-PubMed.27518170.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27518170.s4.e0" e2="DDI-PubMed.27518170.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27518170.s4.e0" e2="DDI-PubMed.27518170.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27518170.s4.e0" e2="DDI-PubMed.27518170.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27518170.s4.e1" e2="DDI-PubMed.27518170.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27518170.s4.e1" e2="DDI-PubMed.27518170.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27518170.s4.e1" e2="DDI-PubMed.27518170.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27518170.s4.e2" e2="DDI-PubMed.27518170.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27518170.s4.e2" e2="DDI-PubMed.27518170.s4.e3" /></sentence><sentence text=" Next, after determining atomoxetine and 4-hydroxyatomoxetine-O-glucuronide plasma concentrations, their pharmacokinetic parameters were calculated using a noncompartmental method and subsequently compared to determine any statistically significant differences between the two periods"><entity charOffset="25-36" id="DDI-PubMed.27518170.s5.e0" text="atomoxetine" /><entity charOffset="41-75" id="DDI-PubMed.27518170.s5.e1" text="4-hydroxyatomoxetine-O-glucuronide" /><pair ddi="false" e1="DDI-PubMed.27518170.s5.e0" e2="DDI-PubMed.27518170.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27518170.s5.e0" e2="DDI-PubMed.27518170.s5.e1" /></sentence><sentence text="" /><sentence text="Bupropion intake influenced all the pharmacokinetic parameters of both atomoxetine and its metabolite"><entity charOffset="0-9" id="DDI-PubMed.27518170.s7.e0" text="Bupropion" /><entity charOffset="71-82" id="DDI-PubMed.27518170.s7.e1" text="atomoxetine" /><pair ddi="false" e1="DDI-PubMed.27518170.s7.e0" e2="DDI-PubMed.27518170.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27518170.s7.e0" e2="DDI-PubMed.27518170.s7.e1" /></sentence><sentence text=" For atomoxetine, Cmax increased from 226±96"><entity charOffset="5-16" id="DDI-PubMed.27518170.s8.e0" text="atomoxetine" /></sentence><sentence text="1 to 386±137 ng/mL and more importantly, AUC0-∞ was significantly increasedfrom 1580±1040 to 8060±4160 ng*h/mL, while the mean t1/2 was prolonged after bupropion pretreatment"><entity charOffset="152-161" id="DDI-PubMed.27518170.s9.e0" text="bupropion" /></sentence><sentence text=" For 4-hydroxyatomoxetine-O-glucuronide, Cmax and AUC0-∞  were decreased from 707±269 to 212±145 ng/mL and from 5750±1240 to 3860±1220 ng*h/mL, respectively"><entity charOffset="5-39" id="DDI-PubMed.27518170.s10.e0" text="4-hydroxyatomoxetine-O-glucuronide" /></sentence><sentence text="" /><sentence text="These results demonstrated that the effect of bupropion on CYP2D6 activity was responsible for an increased systemic exposure to atomoxetine (5"><entity charOffset="46-55" id="DDI-PubMed.27518170.s12.e0" text="bupropion" /><entity charOffset="129-140" id="DDI-PubMed.27518170.s12.e1" text="atomoxetine" /><pair ddi="false" e1="DDI-PubMed.27518170.s12.e0" e2="DDI-PubMed.27518170.s12.e0" /><pair ddi="false" e1="DDI-PubMed.27518170.s12.e0" e2="DDI-PubMed.27518170.s12.e1" /></sentence><sentence text="1-fold) and also for a decreased exposure to its main metabolite (1" /><sentence text="5-fold)" /><sentence text=" Additional studies are required in order to evaluate the clinical relevance of this pharmacokinetic drug interaction" /><sentence text="This article is open to POST-PUBLICATION REVIEW" /><sentence text=" Registered readers (see &quot;For Readers&quot;) may comment by clicking on ABSTRACT on the issue's contents page" /><sentence text="" /></document>